Trefoil Therapeutics Funding: How Much Did They Raise & Key Investors

How Much Did Trefoil Therapeutics Raise?
Funding & Key Investors

Trefoil Therapeutics has solidified its position in the clinical-stage biotechnology sector, securing a total capital infusion of $32.2M. This financial milestone, punctuated by a recent strategic investment of $28M, underscores the market confidence in the firm's proprietary approach to regenerative medicine. By leveraging advanced protein engineering, the company is effectively scaling its operations to address significant unmet needs in ophthalmology, transitioning from early-stage research into a robust clinical development phase.

The recent financing round serves as a critical catalyst for the company, providing the necessary runway to advance its lead candidate, TTHX1114, through complex regulatory and clinical milestones. As the firm continues to attract institutional interest, the focus remains on validating its Fibroblast Growth Factor (FGF1) platform, which represents a paradigm shift in the treatment of corneal endothelial and epithelial diseases.

What is Trefoil Therapeutics?

Trefoil Therapeutics

Manufacturing

Pharmaceuticals

Business Services

Trefoil Therapeutics operates at the intersection of regenerative medicine and ophthalmology, specializing in the development of engineered Fibroblast Growth Factor (FGF1) therapies. The company's core value proposition lies in its dual-modality approach: an intracameral injection designed to treat endothelial decompensation and a topical formulation targeting epithelial damage. By focusing on the underlying cellular mechanisms of corneal health, Trefoil is positioning itself as a leader in restorative eye care, offering a potential alternative to traditional surgical interventions for patients with limited therapeutic options.

How much funding has Trefoil Therapeutics raised?

Trefoil Therapeutics has raised a total of $32.2M across 2 funding rounds:

2016

Private Equity

$4.2M

2019

Series A

$28M

Private Equity (2016): $4.2M, investors not publicly disclosed

Series A (2019): $28M, investors not publicly disclosed

Key Investors in Trefoil Therapeutics

Undisclosed Investor

An institutional capital provider specializing in long-term growth equity and strategic support for high-potential biotechnology firms.

Undisclosed Investor

A venture capital firm focused on early-to-mid-stage life sciences investments, prioritizing companies with disruptive therapeutic platforms.

Undisclosed Investor

A specialized investment group dedicated to funding clinical-stage medical research and innovative drug development programs.

What's next for Trefoil Therapeutics?

With the recent capital injection, Trefoil Therapeutics is poised to accelerate its clinical trial pipeline and expand its manufacturing capabilities. The strategic roadmap involves rigorous data collection for TTHX1114, aiming to demonstrate efficacy in both endothelial and epithelial indications. Future growth will likely hinge on successful phase-gate progression and potential partnerships with larger pharmaceutical entities seeking to bolster their ophthalmic portfolios. As the company matures, the focus will shift toward commercialization readiness and the long-term scalability of its protein-based therapeutic platform, ensuring that its innovative solutions reach a broader patient demographic in the global market.

See full Trefoil Therapeutics company page

See More Financial Insights